nad+ dosage: Frequently asked questions

Verify your dosing protocol first: are you taking the compound daily at the correct dose for your chosen form? Most non-responders are under-dosing (taking 100–200mg when 500mg is required) or dosing inconsistently. If your protocol is correct, consider CD38 activity. Chronic inflammation, obesity, and aging all upregulate this NAD+-degrading enzyme, which can consume NAD+ faster than supplementation replenishes it. Co-supplementing with apigenin (50mg daily) or quercetin (500mg daily) inhibits CD38 and often restores NAD+ responsiveness. Additionally, check timing: dosing NAD+ precursors after large meals or in the evening reduces absorption and enzymatic conversion efficiency.

Reduce your dose by 50% and split it into two administrations (morning and early afternoon) rather than taking it as a single dose. Flushing occurs when NAD+ metabolism generates nicotinamide, which activates GPR109A receptors in skin capillaries. The reaction is harmless but uncomfortable. Splitting doses lowers peak nicotinamide concentration, reducing flushing severity without sacrificing total NAD+ synthesis. If symptoms persist at 300mg daily, switch to a precursor form (NMN or NR) instead of direct NAD+, as precursors generate less nicotinamide per milligram. Nausea typically resolves within 7–10 days as enzymatic tolerance develops.

Take the missed dose as soon as you remember if it's within 12 hours of your scheduled time, then resume your regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and continue with your next scheduled dose. Do not double-dose to compensate. NAD+ precursors don't accumulate in tissues, so missing a single dose drops intracellular NAD+ levels temporarily but doesn't create a deficit that requires catch-up loading. The priority is consistency: one missed dose in a month has negligible impact, but irregular dosing (missing 2–3 doses weekly) prevents sustained NAD+ elevation and negates most benefits.

Sequence administration to avoid competitive transporter interference. NAD+ precursors and compounds like CoQ10, alpha-lipoic acid, or PQQ all rely on similar absorption pathways in the gut and mitochondrial uptake mechanisms. Take NAD+ precursors on an empty stomach in the morning, then administer other mitochondrial compounds with food 4–6 hours later to maximise individual absorption efficiency without saturation competition.

Increase frequency rather than absolute dose. Split 500mg into 250mg doses taken 8–10 hours apart to maintain more consistent plasma NAD+ precursor availability throughout the day. Verify that the formulation contains NMN or NR rather than straight NAD+. Direct NAD+ molecules cannot be absorbed intact through the intestinal wall and must be converted to precursors first, which some low-quality products fail to account for in their labeling.

This is expected. Plasma NAD+ is a poor surrogate marker for intracellular concentrations because NAD+ does not cross cell membranes freely. Functional endpoints (ATP production assays, sirtuin activity markers, mitochondrial respiration rates) are more reliable indicators of tissue NAD+ status than blood tests. If research goals require tissue-level verification, consider muscle biopsy NAD+ quantification or non-invasive MRI phosphocreatine recovery assays as more direct measures.

Reduce your dose by approximately 70–80% to avoid transient nausea or flushing from rapid NAD+ precursor elevation. A researcher taking 500mg oral should start with 100–125mg sublingual and assess tolerance over 5–7 days before increasing further. Allow the sublingual formulation to dissolve completely under the tongue for at least 5 minutes. Swallowing early converts it to an oral dose with the same low bioavailability you were trying to avoid.

Increase by no more than 20% per adjustment and allow 7–10 days before measuring tissue NAD+ levels again. Rapid dose escalation triggers CD38 upregulation that counteracts the intended increase. The enzyme adapts faster than cellular NAD+ synthesis pathways. If baseline tissue NAD+ remains below target after two incremental increases, the issue is likely administration timing rather than total dose. Split daily oral precursor doses into morning and evening administrations to sustain NAD+ synthesis without overwhelming salvage pathway capacity.

Discard it. A 12-hour exposure to 20–25°C reduces NAD+ potency by 20–30% through accelerated hydrolysis. No visual indicator confirms this degradation, so appearance alone cannot verify viability. Administering degraded NAD+ introduces unquantifiable variables into research data. The cost of replacing one vial is substantially lower than the cost of invalid experimental results. Temperature-stable alternatives like lyophilized NMN offer better resilience to storage errors if cold chain management is a recurring constraint.

Yes. CD38 inhibitors like apigenin or quercetin allow 30–40% higher tissue NAD+ levels at identical doses by blocking the primary degradation pathway. Research from the Mayo Clinic demonstrated that combining 500mg NAD+ with 50mg apigenin produced tissue NAD+ elevation equivalent to 750mg NAD+ alone. If your protocol includes CD38 inhibition, start NAD+ dosing at 60–70% of standard protocols and titrate based on measured NAD+ levels. Co-administration timing matters: apigenin should be dosed 30 minutes before NAD+ to achieve peak CD38 inhibition when plasma NAD+ peaks.

Yes, and faster than most users realize. NMN is hygroscopic (absorbs moisture from air) and degrades to nicotinamide when exposed to humidity or temperatures above 25°C for extended periods. A stability study published in Molecules (2020) found that NMN powder stored at room temperature in an unsealed container lost 18% potency within 30 days and 42% within 90 days. Refrigeration at 2–8°C in a sealed, desiccant-protected container preserves potency beyond 12 months. The degradation is invisible. The powder looks identical. So potency loss goes unnoticed until users see no effect despite consistent dosing.

Expect higher acute NAD+ concentrations but shorter duration. IV NAD+ at 100–250mg produces plasma peaks 4–8× higher than oral NMN but clears within 90–120 minutes as tissues rapidly take it up. For sustained metabolic benefit, IV protocols run weekly or biweekly, while oral precursors maintain steady-state NAD+ elevation with daily dosing. IV is logistically intensive and requires clinical administration; oral protocols are self-managed.

Increase to 500mg daily and extend the trial to four weeks. NAD+ restoration is not immediate. Mitochondrial biogenesis and enzyme upregulation take time. A 2020 NMN trial showed plasma NAD+ metabolites increased within 10 days, but subjective energy improvements didn't peak until week four. If no change occurs after four weeks at 500mg, the issue may not be NAD+ depletion. Other factors like thyroid function, iron status, or sleep quality could be limiting cellular energy output independent of NAD+ availability.

Reduce your dose immediately and switch to NR or NMN. Flushing and tingling are classic nicotinamide (NAM) side effects caused by vasodilation from methylation pathway overload. NAM is methylated to N-methylnicotinamide (MNA), which activates G-protein coupled receptors that dilate capillaries. This doesn't occur with NR or NMN because they bypass the methylation step entirely. If you're using NAM at 500mg or higher, drop to 250mg and transition to 300mg NR to achieve equivalent NAD+ elevation without vascular symptoms.

Take your dose in the morning. NAMPT expression follows circadian rhythms, peaking during the light phase when NAD+ biosynthesis is highest. Evening administration delivers precursors when conversion enzymes are downregulated, reducing systemic NAD+ elevation by 30–40% compared to morning dosing. If your research protocol requires evening dosing, split the dose into morning and evening to maintain steady-state levels without overloading conversion pathways at low-activity timepoints.

No. NAD+ synthesis is rate-limited by the enzyme NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide to NMN as the first step in the salvage pathway. Saturating this enzyme with excess substrate doesn't proportionally increase NAD+ output. A 2023 dose-response trial found that NMN doses above 600mg daily produced only marginal increases in intracellular NAD+ (less than 5% additional elevation per 200mg increase), while methylation demand from clearing excess nicotinamide rose significantly. The methylation burden can deplete SAMe (S-adenosylmethionine) reserves, which are critical for dozens of other cellular processes including neurotransmitter synthesis and epigenetic regulation.

This is expected. Cellular NAD+ pools reach steady-state equilibrium when synthesis matches degradation. Plateauing doesn't mean the supplement stopped working; it means your mitochondria are maintaining elevated NAD+ levels. If you're targeting further elevation, increase dose by 100–150mg increments weekly until you reach the therapeutic ceiling (typically 500–750mg for sublingual NR/NMN). Beyond that point, additional dosing increases methylation burden without proportional NAD+ gain.

Yes, significantly. DNA repair processes follow circadian rhythms, with base excision repair (BER) and mismatch repair peaking between 8 PM and 2 AM in most humans. NAD+ from a single morning dose peaks within 60–90 minutes and returns to baseline within 6–8 hours due to constant enzymatic consumption by PARPs, sirtuins, and CD38 (a NAD+-degrading enzyme highly active in aging tissues). If your NAD+ is elevated only during the daytime, you're missing the repair window when damage from oxidative stress accumulated during waking hours is being addressed. Split dosing ensures NAD+ availability spans both phases.

You likely took nicotinic acid (niacin), not nicotinamide riboside or NMN. Niacin causes vasodilation via prostaglandin D2 release, producing the characteristic flush. This is harmless but uncomfortable. Switch to NR or NMN. Neither causes flushing because they bypass the pathway that triggers prostaglandin release. If flushing occurs with NR or NMN, the product may be contaminated or mislabeled.

No. Doses above 500mg produce identical plasma NAD+ levels to 500mg because cellular uptake transporters and conversion enzymes saturate. A 2021 pharmacokinetic study in Nature Metabolism found no difference in NAD+ bioavailability between 600mg and 1000mg NR. The excess converts to methylated metabolites your kidneys excrete within hours. You're paying for urine, not neurons. Stick to 250–500mg and invest the cost difference in cofactors like magnesium or TMG that enhance what you're already taking.